Taking the EZ way: Targeting enhancer of ...
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
URL permanente :
Titre :
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Auteur(s) :
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Salles, G. [Auteur]
Batlevi, C. L. [Auteur]
Tilly, H. [Auteur]
Chaidos, A. [Auteur]
Phillips, T. [Auteur]
Burke, J. [Auteur]
Melnick, A. [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Salles, G. [Auteur]
Batlevi, C. L. [Auteur]
Tilly, H. [Auteur]
Chaidos, A. [Auteur]
Phillips, T. [Auteur]
Burke, J. [Auteur]
Melnick, A. [Auteur]
Titre de la revue :
Blood Reviews
Nom court de la revue :
Blood Rev
Numéro :
56
Pagination :
100988
Éditeur :
Elsevier
Date de publication :
2022-08-01
ISSN :
1532-1681
Mot(s)-clé(s) :
B cell
Epigenomics
EZH2 inhibitor
Lymphoma
Tazemetostat
Epigenomics
EZH2 inhibitor
Lymphoma
Tazemetostat
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that controls the normal biology of germinal B cells. Overexpression or mutation of EZH2 is associated with malignant transformation in a number of B-cell ...
Lire la suite >Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that controls the normal biology of germinal B cells. Overexpression or mutation of EZH2 is associated with malignant transformation in a number of B-cell malignancies; thus, EZH2 inhibitors are an attractive therapeutic option for these targets. Several EZH2 inhibitors have entered clinical trials, but there remains an important question as to how EZH2 inhibitor mechanism of action differs in patients with mutant and wild-type EZH2. This review discusses the EZH2-driven mechanisms that lead to the development of B-cell lymphomas and act as therapeutic targets. Another key area of investigation is whether EZH2 inhibitors will work synergistically with existing immunomodulatory drugs and chemotherapy regimens. In summary, EZH2 inhibitors show potential as treatment for a range of B-cell lymphomas, and numerous clinical evaluations are currently underway.Lire moins >
Lire la suite >Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator that controls the normal biology of germinal B cells. Overexpression or mutation of EZH2 is associated with malignant transformation in a number of B-cell malignancies; thus, EZH2 inhibitors are an attractive therapeutic option for these targets. Several EZH2 inhibitors have entered clinical trials, but there remains an important question as to how EZH2 inhibitor mechanism of action differs in patients with mutant and wild-type EZH2. This review discusses the EZH2-driven mechanisms that lead to the development of B-cell lymphomas and act as therapeutic targets. Another key area of investigation is whether EZH2 inhibitors will work synergistically with existing immunomodulatory drugs and chemotherapy regimens. In summary, EZH2 inhibitors show potential as treatment for a range of B-cell lymphomas, and numerous clinical evaluations are currently underway.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T02:32:17Z
2023-07-05T07:30:39Z
2023-07-05T07:30:39Z